rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    STRO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Sutro at jefferies global healthcare conference: adc push gains pace
      10h agoInvesting.comSTROJEF
      Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
      Nov 12Yahoo FinanceSTRO
      Sutro Biopharma at Stifel 2026 Healthcare Conference 2026: platform push
      Nov 11Investing.comSTROSF
      Here's Why Sutro Biopharma (STRO) is Poised for a Turnaround After Losing 34.2% in 4 Weeks
      Nov 4Yahoo FinanceSTRO
      Sutro Biopharma to Participate in Upcoming Investor Conferences
      Nov 4Yahoo FinanceSTRO
      Down 39.8% in 4 Weeks, Here's Why Sutro Biopharma (STRO) Looks Ripe for a Turnaround
      Nov 3Yahoo FinanceSTRO
      Sutro Biopharma doses first patient in STRO-006 phase 1 trial
      Oct 21Investing.comSTRO
      Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors
      Oct 21Yahoo FinanceSTRO
      H.C. Wainwright reiterates Sutro Biopharma stock rating at buy
      Oct 16Investing.comSTRO
      Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference

      SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 17th Annual World ADC Conference, taking place in San Diego, October 12-15, 2026. “Sutro's presence at World ADC this year reflects meaningful progress across our pipeline, from a plenary presentation on the early clinical saf

      Oct 12Yahoo FinanceSTRO
      Sutro Biopharma appoints Lucas Donigian as business head
      Sep 29Investing.comSTRO
      Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development

      SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Lucas Donigian as Senior Vice President, Business Development, effective September 28, 2026. Mr. Donigian brings more than 20 years of biotechnology industry experience, with a background in business development, corporate strategy

      Sep 29Yahoo FinanceSTRO
      Mackay Gold & Silver Ramps Up Comstock Drilling With Second Rig on Historic Sutro Target

      Tipranks Press Release.

      Aug 21The Globe and MailSTRO

      This is the newest page. Registered accounts read further back.